about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Blast­ing 'spec­u­la­tive com­men­tary,' GSK of­fers up­date on Zan­tac lit­i­ga­tion and vows to 'vig­or­ous­ly de­fend it­self'

3 years ago
Pharma
Law

No­var­tis re­ports two pa­tient deaths af­ter treat­ment with Zol­gens­ma

3 years ago
Pharma

Cit­ing 'chal­leng­ing eco­nom­ic en­vi­ron­ment,' PhI­II-ready mi­cro­bio­me biotech lays off 20% of staffers

3 years ago
People

One year in­to clin­i­cal hold, FDA has more ques­tions about 'pooled' mi­cro­bio­me ther­a­py

3 years ago
FDA+

Who are the women blaz­ing trails in bio­phar­ma R&D? Nom­i­nate them for End­points' 2022 spe­cial re­port

3 years ago
Editor's note

Up­dat­ed: Amid mas­sive re­struc­tur­ing, Bio­gen looks to re­duce phys­i­cal pres­ence in Boston

3 years ago
Pharma

Up­dat­ed: Any­one still look­ing for a CD47? Zai Lab shelves PhI pro­gram af­ter re­view­ing 'com­pet­i­tive land­scape'

3 years ago
R&D

Covid-19 roundup: De­sert­ed by Roche and plagued by set­backs, Atea march­es on; Eu­rope lines up or­der for Mod­er­na's ...

3 years ago
Coronavirus

Ko­di­ak man­ages to score a win for its Eylea ri­val — but the ma­jor test is still ahead

3 years ago
R&D

Q&A: Astel­las' re­tir­ing head of de­vel­op­ment re­flects on gene ther­a­py deaths

3 years ago
People
Cell/Gene Tx

Eli Lil­ly eyes growth out­side In­di­ana in wake of new abor­tion law — and New Jer­sey is ready

3 years ago
People
Pharma

Up­dat­ed: Pfiz­er scoops up Glob­al Blood Ther­a­peu­tics and its sick­le cell ther­a­pies for $5.4B

3 years ago
Deals

A $5B Pfiz­er buy­out? Am­gen, Gilead head­line M&A Thurs­day; Al­ny­lam's AT­TR sweep; An­drew Lo's rare dis­ease quest; and ...

3 years ago
Weekly

Ake­bi­a's ane­mia drug flunked Covid study — but count the bruised biotech 'ex­treme­ly en­cour­aged'

3 years ago
R&D
Coronavirus

Am­gen sweeps last BC­MA BiTE stand­ing out of pipeline

3 years ago
R&D

Astel­las taps sea­soned CMO amid shift to on­col­o­gy; Doug Man­ion steps in­to a new Are­na fol­low­ing $6.7B buy­out

3 years ago
Peer Review

Af­ter get­ting hopes up, ex­pec­ta­tions on Gilead, Ar­cus' CD73 'dimmed' on new up­date

3 years ago
R&D

Sofinno­va, For­bion back $70M push across fin­ish line for rare an­ti­fun­gal treat­ment

3 years ago
Financing

PhI­II fail in over­all sur­vival mea­sure clouds Ipsen's ex­pan­sion plans for can­cer drug Onivyde

3 years ago
R&D

Right as it gets a date with FDA, For­ma of­floads IDH1 in­hibitor to Rigel

3 years ago
Deals

With some neu­ro tar­gets in mind, Ab­b­Vie gets So­sei's drug dis­cov­ery en­gine churn­ing again

3 years ago
Deals
R&D

Lit­tle biotech de­vel­op­ing Genen­tech castoff drug hits hur­dle in glioblas­toma plat­form tri­al

3 years ago
R&D

Cash-strapped biotech flips ex-Med­Im­mune an­ti-in­flam­ma­to­ry drug for $15M cash

3 years ago
Deals

As­traZeneca cuts PhI­II tri­al short af­ter next-gen check­point drug fails in­ter­im analy­sis

3 years ago
R&D
First page Previous page 26272829303132 Next page Last page
A service from the Financial Times